(ATNM) Actinium Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ATNM) Actinium Pharmaceuticals, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Actinium Pharmaceuticals, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Iomab-B Phase III SIERRA
Iomab-B is Actinium Pharmaceuticals, Inc.'s lead Phase III asset in SIERRA for elderly relapsed or refractory AML before BMT, and it is the portfolio's clearest near-term value driver. In SIERRA, 153 patients were randomized; the study showed a 7.1-month median overall survival versus 4.9 months with standard care in the transplant-eligible setting. If approved, it could be Actinium Pharmaceuticals, Inc.'s first commercial launch.
Iomab-B CAR-T conditioning Phase I
Iomab-B’s Phase I CD19 CAR-T conditioning work with Memorial Sloan Kettering broadens Actinium Pharmaceuticals, Inc.’s lead asset beyond AML into a second high-growth cell-therapy use case. The CAR-T market is projected to reach about $30 billion by 2030, so even a modest label extension could matter. It also adds another path for value creation while the AML program is still the core driver.
CD45-targeted conditioning platform
CD45-targeted conditioning is Actinium Pharmaceuticals, Inc.'s core validated platform for transplant prep, and it is the main internal engine behind the pipeline. It fits a market moving toward safer, less toxic conditioning regimens, where reduced chemotherapy exposure is a key need. The platform's BCG view is a Star: high-growth fit, with CD45 as the anchor target.
BMT conditioning market
Actinium Pharmaceuticals, Inc.’s BMT conditioning market is a focused niche: elderly AML patients need safer pre-transplant conditioning, but current chemo-based options remain toxic and often limit transplant use. In the U.S., AML is expected to affect about 20,800 people in 2026, and transplant-eligible older patients still face a clear treatment gap that Actinium’s lead program targets.
- High-need, low-competition niche
- Targets older AML transplant patients
- Built on a clear clinical gap
Cell and gene therapy conditioning expansion
Actinium Pharmaceuticals, Inc.'s conditioning expansion into cellular and adoptive cell therapies targets a fast-growing field that already includes 7 FDA-approved CAR-T products and can scale across multiple indications. This is the clearest long-term commercialization theme in the portfolio because it can be used in more than one therapy setting, not just one drug.
- 7 FDA-approved CAR-T therapies
- Multiple indication expansion
- Strongest long-term growth theme
Iomab-B Could Power Actinium’s Next Growth Surge
Iomab-B is Actinium Pharmaceuticals, Inc.'s Star: a Phase III lead with 153 patients in SIERRA and a 7.1-month median overall survival versus 4.9 months on standard care. It targets a clear transplant gap in older AML, a 2026 U.S. market of about 20,800 cases. CD45 conditioning also gives Actinium Pharmaceuticals, Inc. a second growth path in CAR-T.
| Star | Why it fits | Key data |
|---|---|---|
| Iomab-B | Lead growth driver | Phase III; 153 patients; 7.1 vs 4.9 months |
| CD45 platform | Expands into CAR-T | 2026 AML cases: 20,800 |
What is included in the product
Detailed Word Document
Actinium Pharmaceuticals’ BCG Matrix maps its pipeline units to show where to invest, hold, or divest amid clinical and market risks.
Editable Excel File
Quick BCG snapshot of Actinium Pharmaceuticals, Inc. to pinpoint portfolio strengths, weak spots, and growth bets.
Reference Sources
Actinium Pharmaceuticals, Inc. Reference Sources provide a credible audit trail that speeds diligence and supports better decisions.
Cash Cows
0 approved products
Actinium Pharmaceuticals, Inc. had 0 approved products through end-2025, so it stayed clinical-stage and had no mature asset to fund steady cash flow. That means the classic cash-cow bucket was empty in FY2025, with no recurring product sales to offset R&D spend. Until an approval lands, this segment should be read as zero cash generation, not a source of it.
0 marketed brands
Actinium Pharmaceuticals, Inc. has 0 marketed brands, so it has no commercial therapy to anchor a Cash Cows position. That means there is no entrenched market share or mature pricing power yet. Revenue still hinges on future trial wins and later FDA approval, not on FY2025 product sales.
0 recurring product sales
Actinium Pharmaceuticals, Inc. had no recurring product revenue in FY2025, so its cash cows score is 0. With no approved medicine on the market, operating cash flow stayed negative and dependent on financing, not product sales. That means no asset has yet reached the steady, high-margin sales base needed to act like a cash cow.
0 disclosed royalty streams
Actinium Pharmaceuticals, Inc. has 0 disclosed royalty streams, so there is no meaningful royalty engine from a marketed asset. Royalty income is often the cash cow that funds biotech R&D, but Actinium has not reached that stage. So far, the franchise still depends on pipeline value, not passive cash flow.
- 0 disclosed royalty streams
- No royalty cash cow yet
- Value still tied to pipeline
R&D funded by capital markets
Actinium Pharmaceuticals, Inc. does not fit a true cash-cow profile: it is still funding R&D mainly through equity raises, warrant exercises, and partner support, while clinical work burns cash before any product revenue can scale. In other words, the business is consuming capital to advance its pipeline, not generating surplus cash from a mature drug franchise.
- Financing, not operations, funds R&D.
- Clinical spend keeps cash burn high.
- No durable product cash flow yet.
That makes the asset base look more like a development-stage biotech than a cash cow, since value depends on future trial success, approvals, and non-dilutive funding. Until commercial sales arrive, cash generation stays secondary to capital market access.
Actinium FY2025: No Cash Cows, Just a Pure Pipeline Play
Actinium Pharmaceuticals, Inc. had no cash cows in FY2025: it reported 0 approved products, 0 marketed brands, and 0 disclosed royalty streams, so there was no steady product cash flow to support the business. Operating cash still depended on financing, while R&D burned cash ahead of any approval. This is a pure pipeline-stage profile, not a mature profit engine.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Marketed brands | 0 |
| Royalty streams | 0 |
| Cash cow status | None |
Preview the Actual Deliverable
Actinium Pharmaceuticals, Inc. Reference Sources
You’re previewing the exact Actinium Pharmaceuticals, Inc. BCG Matrix document you’ll receive after purchase. The final file is the same professionally formatted report, with no demo content or hidden changes. Once purchased, it’s ready to download, use, and share right away.
Dogs
Astellas theranostics collaboration
Astellas theranostics collaboration is a partnership, not a commercial product, so it fits the Dogs bucket: low current market share and no disclosed sales or revenue contribution. Actinium Pharmaceuticals, Inc. has not reported any deal value or recurring income from this collaboration, which points to limited proven return so far.
EpicentRx CD47 immunotherapy collaboration
EpicentRx CD47 immunotherapy collaboration sits in the Dog bucket: no marketed product, and the disclosed stage is still early, so cash contribution is minimal. Actinium Pharmaceuticals, Inc. has not shown commercial sales from this program, and without late-stage data or approvals it remains a weak contributor to 2025–2026 value.
AVEO HER3 ARC collaboration
AVEO HER3 ARC remains a Dogs asset in Actinium Pharmaceuticals, Inc.'s BCG Matrix because it targets solid tumors but is still in development. It has no commercial footprint, so there is no 2025 revenue stream to offset R&D spend. That makes it capital-intensive, with payoff still uncertain and tied to future clinical data.
HER2 and HER3 early solid-tumor work
Actinium Pharmaceuticals, Inc.’s HER2 and HER3 early solid-tumor work fits "Dogs": both are concept-stage radioconjugates in crowded oncology fields, with no late-stage proof or market share yet. HER2 already has 10+ approved therapies, and HER3 is being pursued in many trials, so differentiation must be sharp. Without clear efficacy, safety, or biomarker edge, these programs stay low-return.
Concept stage only
No late-stage validation
Crowded HER2/HER3 markets
Weak share, low return risk
Other preclinical isotope programs
Actinium Pharmaceuticals, Inc.’s other preclinical isotope programs sit in the Dogs box because they are still early and cash hungry: several Ac-225, I-131, and Lu-177 assets are spread across multiple targets, but none has proven commercial value yet. Preclinical work usually burns capital before it returns it, so if these programs do not move fast into the clinic, they can become dead weight.
- Early stage, no proven value
- Multiple isotopes, multiple targets
- High cash use before returns
- Slow progress raises drag risk
Actinium’s Dogs Burn Cash With No Near-Term Sales
Actinium Pharmaceuticals, Inc.’s Dogs are early-stage or non-commercial programs with no disclosed 2025–2026 sales, so they add R&D cost but little near-term cash. Astellas, EpicentRx, AVEO HER3, and HER2/HER3 efforts still lack late-stage validation or market share, and that keeps return odds weak.
| Program | Status | 2025–2026 sales | BCG |
|---|---|---|---|
| Astellas | Collaboration | 0 disclosed | Dog |
| EpicentRx CD47 | Early stage | 0 disclosed | Dog |
These assets stay cash hungry until they show clinical wins or a clear commercial path.
Question Marks
Actimab-A CD33 program
Actimab-A is a clinical-stage CD33 asset aimed at AML, where CD33 is present on about 85% to 90% of AML blasts, so the market is real and growing. Still, Actinium Pharmaceuticals, Inc. has no approved product revenue from this program, and its share is tiny versus larger hematology players. In BCG terms, it is a Question Mark: high upside, but it needs more cash, stronger clinical data, and clearer proof of fit to matter.
CD38-targeted radiotherapy program
CD38 is a proven oncology target, with Johnson & Johnson’s Darzalex posting about $11.7 billion in 2024 sales, which shows strong demand in plasma-cell cancers. Actinium Pharmaceuticals, Inc. is still early here, so its CD38-targeted radiotherapy has little clinical or commercial proof yet. That makes it a real question mark: the asset could scale fast if data land well, or fade if efficacy or safety disappoints.
Ac-225 target expansion
Actinium is expanding around actinium-225 radioconjugates for new cancer targets, but it still lacks a dominant share in this niche. Ac-225 has a 9.92-day half-life, which makes supply and scaling hard, so more capital is needed to widen the target base and build manufacturing depth. The market is attractive, but this is still a Question Mark in the BCG Matrix because growth potential is high and control is not yet.
Lu-177 target expansion
Actinium Pharmaceuticals, Inc.'s Lu-177 expansion widens the platform into a fast-growing radiopharmaceutical niche, but the assets are still development-stage and low-share. That makes them a classic BCG Question Mark: strong growth potential, weak market position, and no durable cash flow yet. For Actinium Pharmaceuticals, Inc., the real choice is fund scale-up or exit.
- High growth, low share
- Precommercial asset base
- Needs capital to win
New solid-tumor targets
HER2, HER3, and CD47 are all tied to very large oncology markets, but Actinium Pharmaceuticals, Inc.'s solid-tumor work is still early-stage versus leaders like HER2 antibody-drug conjugates that already generate multibillion-dollar sales. That puts these programs in Question Marks: high upside if data improve, but weak share today. In 2025-2026 terms, the gap is still clinical, not commercial.
- Large markets, low current share
- Early data, not market leaders
- Upside depends on trial wins
Actinium’s Early Bets: Big Upside, Big Risk
Actinium Pharmaceuticals, Inc. Question Marks are early, high-upside programs with low share and no product revenue yet. Actimab-A targets CD33 in AML, a market where CD33 appears in about 85% to 90% of blasts, but it still needs stronger data and capital to win. CD38, HER2, HER3, and CD47 add bigger market upside, yet they remain precommercial.
| Program | Status | Key signal |
|---|---|---|
| Actimab-A | Clinical | CD33 in 85%-90% AML blasts |
| CD38 | Early | Darzalex 2024 sales $11.7B |
| Ac-225 | Platform | Half-life 9.92 days |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.